» Articles » PMID: 31467228

Fusion of the Genes and in Malignant Chondroid Syringoma

Overview
Date 2019 Aug 31
PMID 31467228
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aim: Malignant chondroid syringoma is a rare tumor of unknown pathogenesis.

Materials And Methods: Genetic analyses were performed on a malignant chondroid syringoma.

Results: G-banding analysis of short-term cultured tumor cells yielded the karyotype 46,Y,t(X;6)(p11;p21)[15]/46,XY[2]. RNA sequencing detected an in-frame fusion of PHF1 from 6p21 with TFE3 from Xp11, verified by RT-PCR and Sanger sequencing. Genomic PCR showed that the PHF1-TFE3 junction was identical to the fusion found by RNA sequencing and RT-PCR.

Conclusion: Malignant chondroid syringoma is genetically related to tumors with PHF1 rearrangements such as low-grade endometrial sarcoma and ossifying fibromyxoid tumor, but also with tumors having TFE3 rearrangements such as renal cell carcinoma, alveolar soft part sarcoma, PEComa, and epithelioid hemangioendothelioma. Further investigations on malignant chondroid syringomas are needed in order to determine whether genetic heterogeneity exists among them and the clinical impact of the PHF1-TFE3 fusion.

Citing Articles

A framework for target discovery in rare cancers.

Li B, Sadagopan A, Li J, Wu Y, Cui Y, Konda P bioRxiv. 2024; .

PMID: 39484513 PMC: 11527139. DOI: 10.1101/2024.10.24.620074.


Cytohistological and Immunohistochemical Correlation of Cutaneous Mixed Tumors: A Series of Four Cases and Review of Recent Molecular Updates.

Rathore R, Aggarwal D, Tanveer N, Sharma S Cureus. 2023; 15(10):e47233.

PMID: 38021919 PMC: 10654049. DOI: 10.7759/cureus.47233.


TFE3 nuclear expression as a novel biomarker of ovarian sclerosing stromal tumors and associated with its histological morphology.

Zhao L, Yang Z, Zhou Y, Liu Y, Luo Q, Jiang Q J Ovarian Res. 2023; 16(1):152.

PMID: 37528481 PMC: 10394818. DOI: 10.1186/s13048-023-01241-y.


Polycomb-like Proteins in Gene Regulation and Cancer.

Fischer S, Liefke R Genes (Basel). 2023; 14(4).

PMID: 37107696 PMC: 10137883. DOI: 10.3390/genes14040938.


Malignant chondroid syringoma: A systematic review.

Zufall A, Mark E, Gru A Skin Health Dis. 2023; 3(2):e144.

PMID: 37013126 PMC: 10066760. DOI: 10.1002/ski2.144.


References
1.
Weterman M, van Groningen J, den Hartog A, Geurts van Kessel A . Transformation capacities of the papillary renal cell carcinoma-associated PRCCTFE3 and TFE3PRCC fusion genes. Oncogene. 2001; 20(12):1414-24. DOI: 10.1038/sj.onc.1204213. View

2.
Jo V, Fletcher C . Myoepithelial neoplasms of soft tissue: an updated review of the clinicopathologic, immunophenotypic, and genetic features. Head Neck Pathol. 2015; 9(1):32-8. PMC: 4382482. DOI: 10.1007/s12105-015-0618-0. View

3.
Agaram N, Sung Y, Zhang L, Chen C, Chen H, Singer S . Dichotomy of Genetic Abnormalities in PEComas With Therapeutic Implications. Am J Surg Pathol. 2015; 39(6):813-25. PMC: 4431898. DOI: 10.1097/PAS.0000000000000389. View

4.
Argani P, Zhong M, Reuter V, Fallon J, Epstein J, Netto G . TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers. Am J Surg Pathol. 2016; 40(6):723-37. PMC: 4864095. DOI: 10.1097/PAS.0000000000000631. View

5.
Endo M, Kohashi K, Yamamoto H, Ishii T, Yoshida T, Matsunobu T . Ossifying fibromyxoid tumor presenting EP400-PHF1 fusion gene. Hum Pathol. 2013; 44(11):2603-8. DOI: 10.1016/j.humpath.2013.04.003. View